Incidence and prevalence of non‐melanoma skin cancer in <scp>A</scp>ustralia: A systematic review

Perera, Eshini; Gnaneswaran, Neiraja; Staines, Carolyn; Win, Aung Ko; Sinclair, Rodney

doi:10.1111/ajd.12282

Cited by 188 publications

(167 citation statements)

References 34 publications

(144 reference statements)

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…The incidence of metastatic BCC and SCC ranges between 0.00281–0.05% and 0.5–16%, respectively, whilst the age-adjusted mortality rate is estimated to be 0.12 per 100,000 for BCC and 0.3 per 100,000 for SCC [30–32]. However, despite its relatively low malignant potential, NMSC is associated with a remarkable morbidity and substantial cost [33,34]. …”

Section: Non-melanoma Skin Cancer or Keratinocyte Carcinomasmentioning

confidence: 99%

Epidemiological trends in skin cancer

Apalla

Lallas

Sotiriou

et al. 2017

Dermatol Pract Concept

473

386

View full text Add to dashboard Cite

Skin cancer, including melanoma and non-melanoma skin cancer (NMSC), represents the most common type of malignancy in the white population. The incidence rate of melanoma is increasing worldwide, while the associated mortality remains stable, or is slightly decreasing. On the other hand, the incidence for NMSC varies widely, with the highest rates reported in Australia.In the current review, we highlight recent global trends in epidemiology of skin cancer. We discuss controversial issues raised in current epidemiological data, we analyze the most important risk factors associated with the development of melanoma and NMSC and the impact of skin cancer on health care services. Furthermore, we underline the pressing need for improved registration policies, especially for NMSC, and lastly, we refer to the ongoing primary and secondary prevention strategies and their outcomes so far.

show abstract

Section: Non-melanoma Skin Cancer or Keratinocyte Carcinomasmentioning

confidence: 99%

Epidemiological trends in skin cancer

Apalla

Lallas

Sotiriou

et al. 2017

Dermatol Pract Concept

473

386

View full text Add to dashboard Cite

show abstract

“…The incidence of BCC is rising by around 10% each year (Karagas and Greenberg, 1995) in white populations such as those living in Australia (Perera et al, 2015), yet poor registration of BCC makes it difficult to compare estimates across the world . A range of genetic factors have been associated with BCC and recurrent BCC (Madan et al, 2010), but unlike cutaneous squamous cell carcinoma, the relationship between sun exposure patterns and different types of BCC is still unclear.…”

Section: Introductionmentioning

confidence: 99%

Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial

Williams

Bath‐Hextall

Ozolins

et al. 2017

Journal of Investigative Dermatology

113

106

View full text Add to dashboard Cite

Abbreviations BCC = basal cell carcinoma; nBCC = nodular basal cell carcinoma sBCC = superficial basal cell carcinoma; PDT = photodynamic therapy RCT = randomised controlled trial Abstract -200 words Main text -2600 words Tables -1 Figures -1 References -23 2 ABSTRACT Background: We previously reported modest clinical 3-year benefit for topical imiquimod compared with surgery for superficial or nodular basal cell carcinoma (sBCC, nBCC) at low risk sites in our non-inferiority randomised controlled SINS trial. Here we report 5-year data.Methods: Participants were randomised to imiquimod 5% cream once daily (sBCC, 6 weeks; nBCC, 12 weeks) or excisional surgery (4 mm margin). Primary outcome was clinical absence of initial failure or signs of recurrence at 3 year dermatology review. Five year success was defined as 3 year success plus absence of recurrences identified through hospital, histopathology and general practitioner records. Results:Of 501 participants randomised, 401 contributed to the modified intention-to-treat analyses at year 3 (primary outcome), 383 (96%) of whom had data at year 5. Five year success rates for imiquimod were 82·5% (170/206) compared to 97·7% (173/177) for surgery (relative risk of imiquimod success 0·84, 95% CI 0·77 to 0·91, p<0.001). These were comparable to year 3 success rates of 83·6% (178/213) and 98.4% (185/188), for imiquimod and surgery, respectively. Most imiquimod treatment failures occurred in year one. Interpretation:Although surgery is clearly superior to imiquimod, this study shows sustained benefit for lesions that respond early to topical imiquimod.

show abstract

“…4,5 The vast majority of cases occur on the UV-exposed head and neck region. 6 Although most are localized and curable, advanced disease requires radical surgery and post-operative radiotherapy leading to significant functional morbidity.…”

mentioning

confidence: 99%

PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Programmed cell death (PD-1) and its ligand (PD-L1) inhibitors have shown clinical response in many tumours. PD-L1 data are limited in head and neck cutaneous squamous cell carcinoma (HNcSCC) and no clinical trials of PD-1/PD-L1 inhibitors are published. We performed PD-L1 immunohistochemistry on 74 cases of high risk HNcSCC with 38 matched metastases and evaluated clinicopathological associations, prognostic significance and heterogeneity in matched metastases. We observed PD-L1 expression in >5% of primary tumour cells in 29 cases (39.2%), primary tumour infiltrating lymphocytes (TILs) in 40 cases (70.2%), metastatic tumour cells in 15 cases (39.5%), and metastatic TILs in 18 cases (47.4%). PD-L1 expression in >5% of primary tumour cells was associated with an inflammatory phenotype (p = 0.04), and in primary TILs with clear margins (p = 0.05). PD-L1 expression in >5% of primary tumour cells (p = 0.01), primary TILs (p = 0.001), and metastatic TILs (p = 0.02) was associated with improved disease free survival. PD-L1 expression in >5% of tumour cells was heterogeneous between primary and metastatic tumours in 13 cases (34.2%). PD-L1 expression is common in HNcSCC supporting the rationale for a clinical trial of PD-1/ PD-L1 inhibitors. PD-L1 expression in tumour cells or TILs predicts longer disease free survival and demonstrates temperospatial heterogeneity. Disciplines Medicine and Health Sciences Publication DetailsRoper, E., Lum, T., Palme, C. E., Ashford, B., Ch'ng, S.

show abstract

Incidence and prevalence of non‐melanoma skin cancer in Australia: A systematic review

Cited by 188 publications

References 34 publications

Epidemiological trends in skin cancer

Epidemiological trends in skin cancer

Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial

PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma

Contact Info

Product

Resources

About